IdentiRx

IdentiRx is a biotechnology company focused on the discovery and development of next-generation covalent medicines. Founded by pioneers in chemical biology from the University of California, San Francisco, the company leverages a proprietary platform to identify unique binding pockets and develop highly selective small molecule inhibitors for previously undruggable targets. IdentiRx aims to address significant unmet needs in oncology and other therapeutic areas by utilizing advanced proteomics and chemical screening technologies. The company is currently in the early stages of building its internal pipeline of precision therapies. By targeting specific cysteine residues and other reactive amino acids, IdentiRx seeks to create drugs with enhanced potency and selectivity.